APO Research
Talk to an analyst

APO RESEARCH · REPORT

Medicine for Osteoarthritis Pain

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Medicine for Osteoarthritis Pain Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025193 pages

Choose your research edition.

Industry ResearchMedicine for Osteoarthritis Pain Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Medicine for Osteoarthritis Pain Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Medicine for Osteoarthritis Pain Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Medicine for Osteoarthritis Pain Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Medicine for Osteoarthritis Pain Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Medicine for Osteoarthritis Pain market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Medicine for Osteoarthritis Pain is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Medicine for Osteoarthritis Pain is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Medicine for Osteoarthritis Pain is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Medicine for Osteoarthritis Pain is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Medicine for Osteoarthritis Pain include Abbott, TEVA, Sanofi, Johnson and Johnson, Novartis, Mylan, Eli Lilly, Hengrui Pharmaceutical and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Medicine for Osteoarthritis Pain market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Medicine for Osteoarthritis Pain and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Medicine for Osteoarthritis Pain sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Medicine for Osteoarthritis Pain market size, projected growth trends, production technologies, key applications, and end-use industries.

Medicine for Osteoarthritis Pain Segment by Company

Abbott

TEVA

Sanofi

Johnson and Johnson

Novartis

Mylan

Eli Lilly

Hengrui Pharmaceutical

Pfizer

GlaxoSmithKline

Daiichi Sankyo

Bayer

Tide Pharmaceutical

Iroko Pharmaceuticals

Horizon Pharma

Astellas Pharma

Almatica Pharma

Abiogen Pharma

Medicine for Osteoarthritis Pain Segment by Type

Injection

External

Oral

Medicine for Osteoarthritis Pain Segment by Application

Medical Care

Personal Care

Medicine for Osteoarthritis Pain Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medicine for Osteoarthritis Pain market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Medicine for Osteoarthritis Pain and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medicine for Osteoarthritis Pain.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Medicine for Osteoarthritis Pain market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Medicine for Osteoarthritis Pain manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Medicine for Osteoarthritis Pain in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Medicine for Osteoarthritis Pain in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Medicine for Osteoarthritis Pain Industry Trends Table 2. Medicine for Osteoarthritis Pain Industry Drivers Table 3. Medicine for Osteoarthritis Pain Industry Opportunities and Challenges Table 4. Medicine for Osteoarthritis Pain Industry Restraints Table 5. Global Medicine for Osteoarthritis Pain Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Medicine for Osteoarthritis Pain Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Medicine for Osteoarthritis Pain Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Medicine for Osteoarthritis Pain Sales Market Share by Manufacturers Table 9. Global Medicine for Osteoarthritis Pain Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Medicine for Osteoarthritis Pain Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Medicine for Osteoarthritis Pain Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Medicine for Osteoarthritis Pain Manufacturers, Product Type & Application Table 13. Global Medicine for Osteoarthritis Pain Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Medicine for Osteoarthritis Pain by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Injection Table 17. Major Manufacturers of External Table 18. Major Manufacturers of Oral Table 19. Global Medicine for Osteoarthritis Pain Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Medicine for Osteoarthritis Pain Sales by Type (2021-2026) & (k units) Table 21. Global Medicine for Osteoarthritis Pain Sales by Type (2027-2032) & (k units) Table 22. Global Medicine for Osteoarthritis Pain Sales Market Share by Type (2021-2026) Table 23. Global Medicine for Osteoarthritis Pain Sales Market Share by Type (2027-2032) Table 24. Global Medicine for Osteoarthritis Pain Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Medicine for Osteoarthritis Pain Revenue by Type (2021-2026) & (k units) Table 26. Global Medicine for Osteoarthritis Pain Revenue by Type (2027-2032) & (k units) Table 27. Global Medicine for Osteoarthritis Pain Revenue Market Share by Type (2021-2026) Table 28. Global Medicine for Osteoarthritis Pain Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Medical Care Table 30. Major Manufacturers of Personal Care Table 31. Global Medicine for Osteoarthritis Pain Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Medicine for Osteoarthritis Pain Sales by Application (2021-2026) & (k units) Table 33. Global Medicine for Osteoarthritis Pain Sales by Application (2027-2032) & (k units) Table 34. Global Medicine for Osteoarthritis Pain Sales Market Share by Application (2021-2026) Table 35. Global Medicine for Osteoarthritis Pain Sales Market Share by Application (2027-2032) Table 36. Global Medicine for Osteoarthritis Pain Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Medicine for Osteoarthritis Pain Revenue by Application (2021-2026) & (k units) Table 38. Global Medicine for Osteoarthritis Pain Revenue by Application (2027-2032) & (k units) Table 39. Global Medicine for Osteoarthritis Pain Revenue Market Share by Application (2021-2026) Table 40. Global Medicine for Osteoarthritis Pain Revenue Market Share by Application (2027-2032) Table 41. Global Medicine for Osteoarthritis Pain Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Medicine for Osteoarthritis Pain Sales by Region (2021-2026) & (k units) Table 43. Global Medicine for Osteoarthritis Pain Sales Market Share by Region (2021-2026) Table 44. Global Medicine for Osteoarthritis Pain Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global Medicine for Osteoarthritis Pain Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Medicine for Osteoarthritis Pain Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America Medicine for Osteoarthritis Pain Sales by Country (2021-2026) & (k units) Table 48. North America Medicine for Osteoarthritis Pain Sales by Country (2027-2032) & (k units) Table 49. Europe Medicine for Osteoarthritis Pain Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe Medicine for Osteoarthritis Pain Sales by Country (2021-2026) & (k units) Table 51. Europe Medicine for Osteoarthritis Pain Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific Medicine for Osteoarthritis Pain Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific Medicine for Osteoarthritis Pain Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific Medicine for Osteoarthritis Pain Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa Medicine for Osteoarthritis Pain Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa Medicine for Osteoarthritis Pain Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa Medicine for Osteoarthritis Pain Sales by Country (2027-2032) & (k units) Table 58. Global Medicine for Osteoarthritis Pain Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Medicine for Osteoarthritis Pain Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Medicine for Osteoarthritis Pain Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Medicine for Osteoarthritis Pain Revenue Market Share by Region (2021-2026) Table 62. Global Medicine for Osteoarthritis Pain Revenue Market Share by Region (2027-2032) Table 63. Abbott Company Information Table 64. Abbott Business Overview Table 65. Abbott Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Abbott Medicine for Osteoarthritis Pain Product Portfolio Table 67. Abbott Recent Development Table 68. TEVA Company Information Table 69. TEVA Business Overview Table 70. TEVA Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. TEVA Medicine for Osteoarthritis Pain Product Portfolio Table 72. TEVA Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sanofi Medicine for Osteoarthritis Pain Product Portfolio Table 77. Sanofi Recent Development Table 78. Johnson and Johnson Company Information Table 79. Johnson and Johnson Business Overview Table 80. Johnson and Johnson Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Johnson and Johnson Medicine for Osteoarthritis Pain Product Portfolio Table 82. Johnson and Johnson Recent Development Table 83. Novartis Company Information Table 84. Novartis Business Overview Table 85. Novartis Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Novartis Medicine for Osteoarthritis Pain Product Portfolio Table 87. Novartis Recent Development Table 88. Mylan Company Information Table 89. Mylan Business Overview Table 90. Mylan Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Mylan Medicine for Osteoarthritis Pain Product Portfolio Table 92. Mylan Recent Development Table 93. Eli Lilly Company Information Table 94. Eli Lilly Business Overview Table 95. Eli Lilly Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Eli Lilly Medicine for Osteoarthritis Pain Product Portfolio Table 97. Eli Lilly Recent Development Table 98. Hengrui Pharmaceutical Company Information Table 99. Hengrui Pharmaceutical Business Overview Table 100. Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Product Portfolio Table 102. Hengrui Pharmaceutical Recent Development Table 103. Pfizer Company Information Table 104. Pfizer Business Overview Table 105. Pfizer Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Pfizer Medicine for Osteoarthritis Pain Product Portfolio Table 107. Pfizer Recent Development Table 108. GlaxoSmithKline Company Information Table 109. GlaxoSmithKline Business Overview Table 110. GlaxoSmithKline Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. GlaxoSmithKline Medicine for Osteoarthritis Pain Product Portfolio Table 112. GlaxoSmithKline Recent Development Table 113. Daiichi Sankyo Company Information Table 114. Daiichi Sankyo Business Overview Table 115. Daiichi Sankyo Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Daiichi Sankyo Medicine for Osteoarthritis Pain Product Portfolio Table 117. Daiichi Sankyo Recent Development Table 118. Bayer Company Information Table 119. Bayer Business Overview Table 120. Bayer Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Bayer Medicine for Osteoarthritis Pain Product Portfolio Table 122. Bayer Recent Development Table 123. Tide Pharmaceutical Company Information Table 124. Tide Pharmaceutical Business Overview Table 125. Tide Pharmaceutical Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Tide Pharmaceutical Medicine for Osteoarthritis Pain Product Portfolio Table 127. Tide Pharmaceutical Recent Development Table 128. Iroko Pharmaceuticals Company Information Table 129. Iroko Pharmaceuticals Business Overview Table 130. Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Product Portfolio Table 132. Iroko Pharmaceuticals Recent Development Table 133. Horizon Pharma Company Information Table 134. Horizon Pharma Business Overview Table 135. Horizon Pharma Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Horizon Pharma Medicine for Osteoarthritis Pain Product Portfolio Table 137. Horizon Pharma Recent Development Table 138. Astellas Pharma Company Information Table 139. Astellas Pharma Business Overview Table 140. Astellas Pharma Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Astellas Pharma Medicine for Osteoarthritis Pain Product Portfolio Table 142. Astellas Pharma Recent Development Table 143. Almatica Pharma Company Information Table 144. Almatica Pharma Business Overview Table 145. Almatica Pharma Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Almatica Pharma Medicine for Osteoarthritis Pain Product Portfolio Table 147. Almatica Pharma Recent Development Table 148. Abiogen Pharma Company Information Table 149. Abiogen Pharma Business Overview Table 150. Abiogen Pharma Medicine for Osteoarthritis Pain Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Abiogen Pharma Medicine for Osteoarthritis Pain Product Portfolio Table 152. Abiogen Pharma Recent Development Table 153. Key Raw Materials Table 154. Raw Materials Key Suppliers Table 155. Medicine for Osteoarthritis Pain Distributors List Table 156. Medicine for Osteoarthritis Pain Customers List Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Medicine for Osteoarthritis Pain Product Image Figure 2. Global Medicine for Osteoarthritis Pain Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Medicine for Osteoarthritis Pain Market Size (2021-2032) & (US$ Million) Figure 4. Global Medicine for Osteoarthritis Pain Sales (2021-2032) & (k units) Figure 5. Global Medicine for Osteoarthritis Pain Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Medicine for Osteoarthritis Pain Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Injection Image Figure 9. External Image Figure 10. Oral Image Figure 11. Global Medicine for Osteoarthritis Pain Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Medicine for Osteoarthritis Pain Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Medicine for Osteoarthritis Pain Sales Market Share by Type (2021-2032) Figure 14. Global Medicine for Osteoarthritis Pain Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Medicine for Osteoarthritis Pain Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Medicine for Osteoarthritis Pain Revenue Market Share by Type (2021-2032) Figure 17. Medical Care Image Figure 18. Personal Care Image Figure 19. Global Medicine for Osteoarthritis Pain Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Medicine for Osteoarthritis Pain Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Medicine for Osteoarthritis Pain Sales Market Share by Application (2021-2032) Figure 22. Global Medicine for Osteoarthritis Pain Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Medicine for Osteoarthritis Pain Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Medicine for Osteoarthritis Pain Revenue Market Share by Application (2021-2032) Figure 25. North America Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America Medicine for Osteoarthritis Pain Sales Market Share by Country (2021-2032) Figure 27. U.S. Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Medicine for Osteoarthritis Pain Sales Market Share by Country (2021-2032) Figure 32. Germany Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 33. France Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Medicine for Osteoarthritis Pain Sales Market Share by Country (2021-2032) Figure 39. China Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 43. India Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Medicine for Osteoarthritis Pain Sales Market Share by Country (2021-2032) Figure 47. Brazil Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile Medicine for Osteoarthritis Pain Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global Medicine for Osteoarthritis Pain Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Medicine for Osteoarthritis Pain Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Figure 58. North America Medicine for Osteoarthritis Pain Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Figure 60. Europe Medicine for Osteoarthritis Pain Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Medicine for Osteoarthritis Pain Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Medicine for Osteoarthritis Pain Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Medicine for Osteoarthritis Pain Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Medicine for Osteoarthritis Pain Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • External
  • Oral
Applications
  • Medical Care
  • Personal Care
Companies covered
  • Abbott
  • TEVA
  • Sanofi
  • Johnson and Johnson
  • Novartis
  • Mylan
  • Eli Lilly
  • Hengrui Pharmaceutical
  • Pfizer
  • GlaxoSmithKline
  • Daiichi Sankyo
  • Bayer
  • Tide Pharmaceutical
  • Iroko Pharmaceuticals
  • Horizon Pharma
  • Astellas Pharma
  • Almatica Pharma
  • Abiogen Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Medicine for Osteoarthritis Pain Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Medicine for Osteoarthritis Pain Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Medicine for Osteoarthritis Pain Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Medicine for Osteoarthritis Pain Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Medicine for Osteoarthritis Pain Market Dynamics
  1. 2.1 Medicine for Osteoarthritis Pain Industry Trends
  2. 2.2 Medicine for Osteoarthritis Pain Industry Drivers
  3. 2.3 Medicine for Osteoarthritis Pain Industry Opportunities and Challenges
  4. 2.4 Medicine for Osteoarthritis Pain Industry Restraints
3 Medicine for Osteoarthritis Pain Market by Manufacturers
  1. 3.1 Global Medicine for Osteoarthritis Pain Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Medicine for Osteoarthritis Pain Sales by Manufacturers (2021-2026)
  3. 3.3 Global Medicine for Osteoarthritis Pain Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Medicine for Osteoarthritis Pain Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Medicine for Osteoarthritis Pain Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Medicine for Osteoarthritis Pain Manufacturers, Product Type & Application
  7. 3.7 Global Medicine for Osteoarthritis Pain Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Medicine for Osteoarthritis Pain Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Medicine for Osteoarthritis Pain Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Medicine for Osteoarthritis Pain Tier 1, Tier 2, and Tier 3
4 Medicine for Osteoarthritis Pain Market by Type
  1. 4.1 Medicine for Osteoarthritis Pain Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 External
  4. 4.1.3 Oral
  5. 4.2 Global Medicine for Osteoarthritis Pain Sales by Type
  6. 4.2.1 Global Medicine for Osteoarthritis Pain Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Medicine for Osteoarthritis Pain Sales by Type (2021-2032)
  8. 4.2.3 Global Medicine for Osteoarthritis Pain Sales Market Share by Type (2021-2032)
  9. 4.3 Global Medicine for Osteoarthritis Pain Revenue by Type
  10. 4.3.1 Global Medicine for Osteoarthritis Pain Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Medicine for Osteoarthritis Pain Revenue by Type (2021-2032)
  12. 4.3.3 Global Medicine for Osteoarthritis Pain Revenue Market Share by Type (2021-2032)
5 Medicine for Osteoarthritis Pain Market by Application
  1. 5.1 Medicine for Osteoarthritis Pain Application Introduction
  2. 5.1.1 Medical Care
  3. 5.1.2 Personal Care
  4. 5.2 Global Medicine for Osteoarthritis Pain Sales by Application
  5. 5.2.1 Global Medicine for Osteoarthritis Pain Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Medicine for Osteoarthritis Pain Sales by Application (2021-2032)
  7. 5.2.3 Global Medicine for Osteoarthritis Pain Sales Market Share by Application (2021-2032)
  8. 5.3 Global Medicine for Osteoarthritis Pain Revenue by Application
  9. 5.3.1 Global Medicine for Osteoarthritis Pain Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Medicine for Osteoarthritis Pain Revenue by Application (2021-2032)
  11. 5.3.3 Global Medicine for Osteoarthritis Pain Revenue Market Share by Application (2021-2032)
6 Global Medicine for Osteoarthritis Pain Sales by Region
  1. 6.1 Global Medicine for Osteoarthritis Pain Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Medicine for Osteoarthritis Pain Sales by Region (2021-2032)
  3. 6.2.1 Global Medicine for Osteoarthritis Pain Sales by Region (2021-2026)
  4. 6.2.2 Global Medicine for Osteoarthritis Pain Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Medicine for Osteoarthritis Pain Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Medicine for Osteoarthritis Pain Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Medicine for Osteoarthritis Pain Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Medicine for Osteoarthritis Pain Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Medicine for Osteoarthritis Pain Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Medicine for Osteoarthritis Pain Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Medicine for Osteoarthritis Pain Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Medicine for Osteoarthritis Pain Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Medicine for Osteoarthritis Pain Revenue by Region
  1. 7.1 Global Medicine for Osteoarthritis Pain Revenue by Region
  2. 7.1.1 Global Medicine for Osteoarthritis Pain Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Medicine for Osteoarthritis Pain Revenue by Region (2021-2026)
  4. 7.1.3 Global Medicine for Osteoarthritis Pain Revenue by Region (2027-2032)
  5. 7.1.4 Global Medicine for Osteoarthritis Pain Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Medicine for Osteoarthritis Pain Revenue (2021-2032)
  8. 7.2.2 North America Medicine for Osteoarthritis Pain Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Medicine for Osteoarthritis Pain Revenue (2021-2032)
  11. 7.3.2 Europe Medicine for Osteoarthritis Pain Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Medicine for Osteoarthritis Pain Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Medicine for Osteoarthritis Pain Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Medicine for Osteoarthritis Pain Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Medicine for Osteoarthritis Pain Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Medicine for Osteoarthritis Pain Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 TEVA
  8. 8.2.1 TEVA Company Information
  9. 8.2.2 TEVA Business Overview
  10. 8.2.3 TEVA Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 TEVA Medicine for Osteoarthritis Pain Product Portfolio
  12. 8.2.5 TEVA Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Medicine for Osteoarthritis Pain Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson and Johnson
  20. 8.4.1 Johnson and Johnson Company Information
  21. 8.4.2 Johnson and Johnson Business Overview
  22. 8.4.3 Johnson and Johnson Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson and Johnson Medicine for Osteoarthritis Pain Product Portfolio
  24. 8.4.5 Johnson and Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Medicine for Osteoarthritis Pain Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Mylan
  32. 8.6.1 Mylan Company Information
  33. 8.6.2 Mylan Business Overview
  34. 8.6.3 Mylan Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Mylan Medicine for Osteoarthritis Pain Product Portfolio
  36. 8.6.5 Mylan Recent Developments
  37. 8.7 Eli Lilly
  38. 8.7.1 Eli Lilly Company Information
  39. 8.7.2 Eli Lilly Business Overview
  40. 8.7.3 Eli Lilly Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly Medicine for Osteoarthritis Pain Product Portfolio
  42. 8.7.5 Eli Lilly Recent Developments
  43. 8.8 Hengrui Pharmaceutical
  44. 8.8.1 Hengrui Pharmaceutical Company Information
  45. 8.8.2 Hengrui Pharmaceutical Business Overview
  46. 8.8.3 Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Product Portfolio
  48. 8.8.5 Hengrui Pharmaceutical Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Medicine for Osteoarthritis Pain Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 GlaxoSmithKline
  56. 8.10.1 GlaxoSmithKline Company Information
  57. 8.10.2 GlaxoSmithKline Business Overview
  58. 8.10.3 GlaxoSmithKline Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GlaxoSmithKline Medicine for Osteoarthritis Pain Product Portfolio
  60. 8.10.5 GlaxoSmithKline Recent Developments
  61. 8.11 Daiichi Sankyo
  62. 8.11.1 Daiichi Sankyo Company Information
  63. 8.11.2 Daiichi Sankyo Business Overview
  64. 8.11.3 Daiichi Sankyo Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Daiichi Sankyo Medicine for Osteoarthritis Pain Product Portfolio
  66. 8.11.5 Daiichi Sankyo Recent Developments
  67. 8.12 Bayer
  68. 8.12.1 Bayer Company Information
  69. 8.12.2 Bayer Business Overview
  70. 8.12.3 Bayer Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bayer Medicine for Osteoarthritis Pain Product Portfolio
  72. 8.12.5 Bayer Recent Developments
  73. 8.13 Tide Pharmaceutical
  74. 8.13.1 Tide Pharmaceutical Company Information
  75. 8.13.2 Tide Pharmaceutical Business Overview
  76. 8.13.3 Tide Pharmaceutical Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Tide Pharmaceutical Medicine for Osteoarthritis Pain Product Portfolio
  78. 8.13.5 Tide Pharmaceutical Recent Developments
  79. 8.14 Iroko Pharmaceuticals
  80. 8.14.1 Iroko Pharmaceuticals Company Information
  81. 8.14.2 Iroko Pharmaceuticals Business Overview
  82. 8.14.3 Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Product Portfolio
  84. 8.14.5 Iroko Pharmaceuticals Recent Developments
  85. 8.15 Horizon Pharma
  86. 8.15.1 Horizon Pharma Company Information
  87. 8.15.2 Horizon Pharma Business Overview
  88. 8.15.3 Horizon Pharma Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Horizon Pharma Medicine for Osteoarthritis Pain Product Portfolio
  90. 8.15.5 Horizon Pharma Recent Developments
  91. 8.16 Astellas Pharma
  92. 8.16.1 Astellas Pharma Company Information
  93. 8.16.2 Astellas Pharma Business Overview
  94. 8.16.3 Astellas Pharma Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Astellas Pharma Medicine for Osteoarthritis Pain Product Portfolio
  96. 8.16.5 Astellas Pharma Recent Developments
  97. 8.17 Almatica Pharma
  98. 8.17.1 Almatica Pharma Company Information
  99. 8.17.2 Almatica Pharma Business Overview
  100. 8.17.3 Almatica Pharma Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Almatica Pharma Medicine for Osteoarthritis Pain Product Portfolio
  102. 8.17.5 Almatica Pharma Recent Developments
  103. 8.18 Abiogen Pharma
  104. 8.18.1 Abiogen Pharma Company Information
  105. 8.18.2 Abiogen Pharma Business Overview
  106. 8.18.3 Abiogen Pharma Medicine for Osteoarthritis Pain Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Abiogen Pharma Medicine for Osteoarthritis Pain Product Portfolio
  108. 8.18.5 Abiogen Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Medicine for Osteoarthritis Pain Value Chain Analysis
  2. 9.1.1 Medicine for Osteoarthritis Pain Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Medicine for Osteoarthritis Pain Production Mode & Process
  6. 9.2 Medicine for Osteoarthritis Pain Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Medicine for Osteoarthritis Pain Distributors
  9. 9.2.3 Medicine for Osteoarthritis Pain Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst